Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/52032 |
Resumo: | Conselho Nacional de Pesquisa do Brasil. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. Fundação Oswaldo Cruz. JBS. Instituto de Saúde Carlos III. Ministério da Ciência e Inovação da Espanha. Generalitat de Catalunya. |
| id |
CRUZ_adb5a883a5129095d8cfb57361c23832 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/52032 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Silva, Thiago CerqueiraAndrews, Jason R.Boaventura, Viviane S.Ranzani, Otavio T.Oliveira, Vinicius de AraújoPaixão, Enny S.Bertoldo Júnior, JuracyMachado, Tales MotaHitchings, Matt D. T.Dorion, MuriloLind, Margaret L.Penna, Gerson O.Cummings, Derek A. T.Dean, Natalie E.Werneck, Guilherme LoureiroPearce, NeilBarreto, Mauricio L.Ko, Albert I.Croda, JulioBarral-Netto, Manoel2022-04-05T13:31:12Z2022-04-05T13:31:12Z2022SILVA, Thiago Cerqueira et.al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. The Lancet Infectious Diseases, p. 1-11, 2022.1474-4457https://www.arca.fiocruz.br/handle/icict/5203210.1016/S1473-3099(22)00140-2Conselho Nacional de Pesquisa do Brasil. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. Fundação Oswaldo Cruz. JBS. Instituto de Saúde Carlos III. Ministério da Ciência e Inovação da Espanha. Generalitat de Catalunya.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil. /Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, USA.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.Barcelona Institute for Global Health, Barcelona, Spain / Faculdade de Medicina. Hospital das Clínicas. Instituto do Coração. Divisão de Pneumologia. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.London School of Hygiene & Tropical Medicine. Department of Infectious Disease Epidemiology. London, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.Universidade Federal de Ouro Preto. Diretoria de Tecnologia da Informação. Ouro Preto, MG, Brasil.University of Florida. Department of Biostatistics. College of Public Health & Health Professions. Gainesville, FL, USA.Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, CT, USA.Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, CT, USA.Universidade de Brasília. Núcleo de Medicina Tropical. Brasília, DF, Brasil / Escola Fiocruz de Governo. Fiocruz Brasília. Brasília, DF, Brasil.University of Florida. Department of Biology. Emerging Pathogens Institute Gainesville, FL, USA.Department of Biostatistics & Bioinformatics. Rollins School of Public Health. Emory University. Atlanta, GA, USA.Universidade do Estado do Rio de Janeiro. Departamento de Epidemiologia. Rio de Janeiro, RJ, Brasil.London School of Hygiene & Tropical Medicine. Department of Medical Statistics. London, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, CT, USA.Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, CT, USA. / Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil / Fiocruz Mato Grosso do Sul. Campo Grande. MS, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Instituto de Saúde Coletiva. Salvador, BA, Brasil.Background: COVID-19 vaccines have proven highly effective among individuals without a previous SARS-CoV-2 infection, but their effectiveness in preventing symptomatic infection and severe outcomes among individuals with previous infection is less clear. We aimed to estimate the effectiveness of four COVID-19 vaccines against symptomatic infection, hospitalisation, and death for individuals with laboratory-confirmed previous SARS-CoV-2 infection. Methods: Using national COVID-19 notification, hospitalisation, and vaccination datasets from Brazil, we did a test-negative, case-control study to assess the effectiveness of four vaccines (CoronaVac [Sinovac], ChAdOx1 nCoV-19 [AstraZeneca], Ad26.COV2.S [Janssen], and BNT162b2 [Pfizer-BioNtech]) for individuals with laboratory-confirmed previous SARS-CoV-2 infection. We matched cases with RT-PCR positive, symptomatic COVID-19 with up to ten controls with negative RT-PCR tests who presented with symptomatic illnesses, restricting both groups to tests done at least 90 days after an initial infection. We used multivariable conditional logistic regression to compare the odds of test positivity and the odds of hospitalisation or death due to COVID-19, according to vaccination status and time since first or second dose of vaccines. Findings: Between Feb 24, 2020, and Nov 11, 2021, we identified 213 457 individuals who had a subsequent, symptomatic illness with RT-PCR testing done at least 90 days after their initial SARS-CoV-2 infection and after the vaccination programme started. Among these, 30 910 (14·5%) had a positive RT-PCR test consistent with reinfection, and we matched 22 566 of these cases with 145 055 negative RT-PCR tests from 68 426 individuals as controls. Among individuals with previous SARS-CoV-2 infection, vaccine effectiveness against symptomatic infection 14 or more days from vaccine series completion was 39·4% (95% CI 36·1–42·6) for CoronaVac, 56·0% (51·4–60·2) for ChAdOx1 nCoV-19, 44·0% (31·5–54·2) for Ad26.COV2.S, and 64·8% (54·9–72·4) for BNT162b2. For the two-dose vaccine series (CoronaVac, ChAdOx1 nCoV-19, and BNT162b2), effectiveness against symptomatic infection was significantly greater after the second dose than after the first dose. Effectiveness against hospitalisation or death 14 or more days from vaccine series completion was 81·3% (75·3–85·8) for CoronaVac, 89·9% (83·5–93·8) for ChAdOx1 nCoV-19, 57·7% (−2·6 to 82·5) for Ad26.COV2.S, and 89·7% (54·3–97·7) for BNT162b2. Interpretation: All four vaccines conferred additional protection against symptomatic infections and severe outcomes among individuals with previous SARS-CoV-2 infection. The provision of a full vaccine series to individuals after recovery from COVID-19 might reduce morbidity and mortality.engElsevierCOVID-19EfetividadeValor Preditivo dos TestesBrasilCOVID-19EffectivenessPredictive Value of TestsBrazilCOVID-19EfectividadValor Predictivo de las PruebasBrasilSARS-CoV-2Efficacité (Effectiveness)Valeur prédictive des testsBrésilEffectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/52032/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALSilva, Thiago C. - Effectiveness of CoronaVac, ChAdOx1 nCoV-19,.pdfSilva, Thiago C. - Effectiveness of CoronaVac, ChAdOx1 nCoV-19,.pdfapplication/pdf1628585https://www.arca.fiocruz.br/bitstream/icict/52032/2/Silva%2c%20Thiago%20C.%20-%20Effectiveness%20of%20CoronaVac%2c%20ChAdOx1%20nCoV-19%2c.pdf85cacaccf53d666af95716087e6290deMD52icict/520322023-03-15 14:34:22.701oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:22Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study |
| title |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study |
| spellingShingle |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study Silva, Thiago Cerqueira COVID-19 Efetividade Valor Preditivo dos Testes Brasil COVID-19 Effectiveness Predictive Value of Tests Brazil COVID-19 Efectividad Valor Predictivo de las Pruebas Brasil SARS-CoV-2 Efficacité (Effectiveness) Valeur prédictive des tests Brésil |
| title_short |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study |
| title_full |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study |
| title_fullStr |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study |
| title_full_unstemmed |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study |
| title_sort |
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study |
| author |
Silva, Thiago Cerqueira |
| author_facet |
Silva, Thiago Cerqueira Andrews, Jason R. Boaventura, Viviane S. Ranzani, Otavio T. Oliveira, Vinicius de Araújo Paixão, Enny S. Bertoldo Júnior, Juracy Machado, Tales Mota Hitchings, Matt D. T. Dorion, Murilo Lind, Margaret L. Penna, Gerson O. Cummings, Derek A. T. Dean, Natalie E. Werneck, Guilherme Loureiro Pearce, Neil Barreto, Mauricio L. Ko, Albert I. Croda, Julio Barral-Netto, Manoel |
| author_role |
author |
| author2 |
Andrews, Jason R. Boaventura, Viviane S. Ranzani, Otavio T. Oliveira, Vinicius de Araújo Paixão, Enny S. Bertoldo Júnior, Juracy Machado, Tales Mota Hitchings, Matt D. T. Dorion, Murilo Lind, Margaret L. Penna, Gerson O. Cummings, Derek A. T. Dean, Natalie E. Werneck, Guilherme Loureiro Pearce, Neil Barreto, Mauricio L. Ko, Albert I. Croda, Julio Barral-Netto, Manoel |
| author2_role |
author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Silva, Thiago Cerqueira Andrews, Jason R. Boaventura, Viviane S. Ranzani, Otavio T. Oliveira, Vinicius de Araújo Paixão, Enny S. Bertoldo Júnior, Juracy Machado, Tales Mota Hitchings, Matt D. T. Dorion, Murilo Lind, Margaret L. Penna, Gerson O. Cummings, Derek A. T. Dean, Natalie E. Werneck, Guilherme Loureiro Pearce, Neil Barreto, Mauricio L. Ko, Albert I. Croda, Julio Barral-Netto, Manoel |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 Efetividade Valor Preditivo dos Testes Brasil |
| topic |
COVID-19 Efetividade Valor Preditivo dos Testes Brasil COVID-19 Effectiveness Predictive Value of Tests Brazil COVID-19 Efectividad Valor Predictivo de las Pruebas Brasil SARS-CoV-2 Efficacité (Effectiveness) Valeur prédictive des tests Brésil |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 Effectiveness Predictive Value of Tests Brazil |
| dc.subject.es.pt_BR.fl_str_mv |
COVID-19 Efectividad Valor Predictivo de las Pruebas Brasil |
| dc.subject.fr.pt_BR.fl_str_mv |
SARS-CoV-2 Efficacité (Effectiveness) Valeur prédictive des tests Brésil |
| description |
Conselho Nacional de Pesquisa do Brasil. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. Fundação Oswaldo Cruz. JBS. Instituto de Saúde Carlos III. Ministério da Ciência e Inovação da Espanha. Generalitat de Catalunya. |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-04-05T13:31:12Z |
| dc.date.available.fl_str_mv |
2022-04-05T13:31:12Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
SILVA, Thiago Cerqueira et.al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. The Lancet Infectious Diseases, p. 1-11, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/52032 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1474-4457 |
| dc.identifier.doi.none.fl_str_mv |
10.1016/S1473-3099(22)00140-2 |
| identifier_str_mv |
SILVA, Thiago Cerqueira et.al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. The Lancet Infectious Diseases, p. 1-11, 2022. 1474-4457 10.1016/S1473-3099(22)00140-2 |
| url |
https://www.arca.fiocruz.br/handle/icict/52032 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/52032/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/52032/2/Silva%2c%20Thiago%20C.%20-%20Effectiveness%20of%20CoronaVac%2c%20ChAdOx1%20nCoV-19%2c.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 85cacaccf53d666af95716087e6290de |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813008863070257152 |